NewAmsterdam aces Phase 3 trial, but investors are skeptical

Nicole DeFeudis

Editor

NewAmsterdam Pharma’s lead cardio program obicetrapib passed another Phase 3 trial, demonstrating its ability to lower “bad cholesterol” in combination with a drug called ezetimibe …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

NewAmsterdam aces Phase 3 trial, but investors are skeptical

Nicole DeFeudis

Editor

Sign up to read this article for free.

Pfizer partners with two more Flagship biotechs on obesity, cancer

Post-Hoc: RFK vs. Vivek, and the future of US drug policy

FDA updates label of 33-year-old cancer drug with new dose and warning

Carolyn Bertozzi’s latest biotech debuts with $30M seed round and a sugary spin on immunotherapy

Novo and Viking present new MASH data, but analysts remain confident in Madrigal's Rezdiffra

Are programs with compounded GLP-1s safe for your population?

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

Nicole DeFeudis

Editor

Sign up to read this article for free.

Pfiz­er part­ners with two more Flag­ship biotechs on obe­si­ty, can­cer

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Car­olyn Bertozzi’s lat­est biotech de­buts with $30M seed round and a sug­ary spin on im­munother­a­py

No­vo and Viking present new MASH da­ta, but an­a­lysts re­main con­fi­dent in Madri­gal's Rezd­if­fra

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

NewAmsterdam aces Phase 3 trial, but investors are skeptical

Pfizer partners with two more Flagship biotechs on obesity, cancer

Post-Hoc: RFK vs. Vivek, and the future of US drug policy

FDA updates label of 33-year-old cancer drug with new dose and warning

Carolyn Bertozzi’s latest biotech debuts with $30M seed round and a sugary spin on immunotherapy

Novo and Viking present new MASH data, but analysts remain confident in Madrigal's Rezdiffra

Are programs with compounded GLP-1s safe for your population?